Emeis Stock Falls by 3.44% to €14.61 Despite a Yearly Gain of 32.77%
The Emeis stock has fallen by 3.44% to €14.61 at midday on this Monday, May 11, 2026, within a SBF 120 that is down by 0.85%. The stock is among the top ten declines of the index, following a week marked by the release of a strong quarterly revenue figure. However, it still maintains a yearly gain of 32.77%.
A Notable Decline Following Q1 Publication
Emeis is ranked 117th in the SBF 120 for the session, among the most significant drops in the broad index. This movement comes a few days after the publication of the first quarter revenue, which showed an organic growth of 6.3% and confirmed the EBITDAR guidance for 2026 (growth exceeding 10%). The session is generally unfavorable for European stocks, with the CAC 40 down by 0.96% amid ongoing tensions in the Middle East and rising Brent prices above $103. Nevertheless, the stock is still up by 1.95% for the week and 32.77% over twelve months, reflecting the recovery trajectory of the group of retirement homes and clinics initiated since 2024.
Price Still Above Its Moving Averages
Despite today's decline, the price at €14.61 remains above its three moving averages: MM20 at €14.24, MM50 at €14.03, and MM200 at €13.70. The RSI at 62 indicates a buying momentum still present, without excess. The stock is trading in the upper part of the Bollinger Bands (66%), with an upper limit at €15.43, which is close to the resistance identified at €15.29. According to TP Icap Midcap, the target price set at €17 in a recent note offers a theoretical potential of over 16% compared to today's price. The appointment of Jean-Marc Boursier as Deputy CEO, effective July 1, 2026, remains an upcoming milestone in governance. The technical support is located at €12.26.
